NASA Patents New Faster, Cheaper Route to the Moon

A record published by the US Patent and Trademark Office recently called attention even though it did not reveal equipment or technology. It is a new trajectory for the Moon, developed by NASA engineers. The unprecedented route for travel to the natural satellite saves money, time and fuel, as well as providing unprecedented discoveries about the Universe for the first mission to explore it.

Through this technique, smaller spacecraft can hitch a ride on missions launched to Geosynchronous Earth Orbit, a region that is the destination of many satellites. There, they would be able to perform a series of maneuvers at any time of the year and without restrictions on time and inclination to enter lunar orbit, making a faster trip and with little or no fuel.

Due to its characteristics, it is aimed at spaceships of reduced size and low budget, so larger missions, with spacecraft carrying astronauts and rovers, cannot benefit from this route.

DAPPER Mission

One of the first missions to use the new path to the Moon will be the Dark Ages Polarimeter Pathfinder (DAPPER), a project created by astrophysicists at the University of Colorado (USA). The same size as a microwave, the spacecraft is compact enough to travel as a secondary payload in a larger spacecraft to geosynchronous orbit and from there begin its journey to the Moon using only “a modest fuel tank” for adjustments. steering.

Still with no scheduled launch date, DAPPER will pick up low-frequency radio signals from the dark side of the Moon, from 13 billion years ago, avoiding interference caused by Earth’s electronic devices. By escaping these blockages, the equipment can find evidence of the first stars, black holes and galaxies formed about 500 million years after the Big Bang.

Source: Tecmundo

Butantan registra patente de vacina contra E. coli

Butantan registers patent for vaccine against E. coli

After receiving patent approval for a vaccine against the enteropathogenic Escherichia coli bacteria, the Butantan Institute is working on the development of an immunizing agent against the disease, capable of causing diarrhea that leads to death. Also known by the acronym EPEC, an enteropathogenic Escherichia coli is one of the six pathogenic categories of E. coli that cause intestinal disease. Transmitted via the fecal-oral route, that is, through the ingestion of contaminated water or food, it is common in developing countries due to the lack of basic sanitation, and annually kills up to 2 million children worldwide from diarrhea.

The issue sensitized Wilmar Dias da Silva’s professor and researcher at Butantan in 2005, during the Thematic Cooperation Program in the Matter of Science and Technology (Proáfrica), a technology transfer project for the creation of a serpentarium in Mozambique. Back in Brazil, he devised a recombinant vaccine to fight the disease. In this type of immunizing agent, which is obtained through genetic engineering, there is a combination of DNA or RNA from different organisms, the result of which is inserted into a vector – in this case, the chosen one was the BCG bacterium, which is widely used in research for its safety and immunogenic properties.

Who accepted the challenge of taking the project forward, under the supervision of Wilmar and researcher Roxane Piazza, from the Bacteriology Laboratory, among other scientists from the Butantan, was the then master’s student at the University of São Paulo (USP) Halyka Vasconcellos. “We inserted the genes of two proteins, BFPA, and intimin, which are responsible for the adhesion of EPEC in the intestine, inside the BCG. We then applied this modified BCG in mice, generating a positive immune response”, summarizes the researcher. The work was published in the renowned journal Vaccine, in 2012, but continued to be improved by Halyka throughout her doctorate and postdoctoral studies, until the patent registration was submitted and approved, in May this year, by the Brazilian Patent Office (BPTO).

“It was the realization of a dream, which I would not have realized without the contribution of numerous researchers from Butantan who helped me along this path”, says Halyka, who is now a university professor and directs two laboratories in Nova Friburgo (RJ). Besides her, Wilmar and Roxane, scientists Karina Scaramuzzi, Ivan Pereira Nascimento, Jorge da Costa Ferreira Junior, Cecilia Abe, and Andre Kipnis are also listed as inventors of the patent, due to their technical contribution. “We do not work interested in personal profit, but in the good that a vaccine will bring to society”, emphasizes Professor Wilmar.

The next stage of the research will be the realization of pre-clinical and clinical trials (phases 1, 2, and 3). “We still have a long way to go, but the approval of the patent will certainly facilitate the negotiation of this new technology”, celebrates the innovation manager at Butantan, Cristiano Gonçalves Pereira.

Source: Pfarma


BPTO will publish announcements of IP assets for commercialization

In order to facilitate the transfer of technology and the licensing of industrial property assets, BPTO launched (on 09/15) the IP showcase project, an online system for the publication of advertisements, which will enable commercialization, as of October 1, of patent applications or patents granted. The Institute’s new service was approved by Ordinance No. 331/2020, published in the Intellectual Property Magazine No. 2593.

The proposal is that, later, other IP assets are added to the platform.

Through the IP Showcase project, those interested in new technological solutions will be able to identify those that are available for commercialization, while the developers of these technologies will have the possibility to exhibit their products on a platform specially developed by the Institute.

The negotiation between the parties will not generate civil or administrative responsibility on the part of the BPTO, including with regard to the eventual rejection of patent applications.

News from: BPTO


Brazilian scientists create serum with horse antibodies capable of neutralizing COVID-19

A serum entirely developed in Brazil showed neutralizing antibodies up to 50 times more potent against Sars-CoV-2 than those present in the blood plasma of people who had COVID-19. The result was considered excellent by the scientists who developed the product and paves the way for a more efficient treatment against the disease. The researchers await authorization from the National Health Surveillance Agency (Anvisa) to begin testing the serum in humans.

Plasma from people who have had COVID is already being used to treat the disease, as a way to offer extra antibodies to patients who are still struggling to fight the virus. The serum principle is similar.

The difference is that it is being produced on horses and, according to the first results, it is much more potent. These antibodies are then purified and can be injected into patients.

“We have to do everything very carefully so as not to create false illusions”, pondered the president of the Rio Research Foundation (Faperj), Jerson Lima Silva, who is a researcher at the Federal University of Rio de Janeiro (UFRJ) and participated in the project. “But the response was impressive, well above our expectations.”

The work will be submitted for publication on Thursday, 13, in a scientific session at the National Academy of Medicine (ANM). On the same occasion, Lima Silva, who is a researcher at UFRJ and participates in the project, will announce the filing of a serum patent.

In May, five horses from the Vital Brazil Institute (IVB) were inoculated with a recombinant S protein from the coronavirus produced at Coppe / UFRJ. After 70 days, the plasmas of four animals showed antibodies 20 to 50 times more potent against COVID-19. The fifth animal also showed antibodies but in a smaller volume.

“We are all thrilled with the result”, said the president of Instituto Vital Brazil, Adilson Stolet. “It was very good, excellent, wonderful.”

According to Lima Silva, one of the reasons for obtaining such a good immune response, both in terms of detected antibodies and its ability to kill the virus, is that scientists used an entire recombinant protein and not just fragments.

The protein S produced at the Cell Culture Engineering Laboratory at Coppe / UFRJ also led to the development of a new serological test for the detection of antibodies to COVID-19.

Serotherapy is a successful treatment, used for decades against diseases such as rabies and tetanus and also for the bites of bees, snakes and other venomous animals, such as spiders and scorpions. Serums produced by IVB have excellent results for clinical use, with no history of hypersensitivity or other possible adverse reactions.

“One of the advantages is precise that we have been using serums for a century, such as anti-phage and anti-tetanus,” said Adilson Stolet. “Not to mention the volume of plasma that can be produced. We have 300 animals, but we can buy another 500; in two months we would have an enormous amount of antibodies.”

As it is a well-known technology, the researchers hope to be able to skip the pre-clinical testing phase and go straight to testing with humans. There is already a partnership signed with the DOr Research and Teaching Institute (IDOR) for testing.

“Even if we do not achieve 100% efficiency, it could be a strategy to also combine this therapy with the vaccine”, concluded Lima Silva.

News from: UOL


Federal Regional Court decides that the term “Botox” is a trademark and rejects the request to cancel the registration

After nine years awaiting a decision at the second instance and 14 years after the lawsuit was filed, the 11th Panel of the Federal Regional Court of the 3rd Region decided that the term “Botox” is a trademark and is not to be confused with the substance botulinum toxin. The discussion took place in Civil Appeal 0000616-76.2006.4.03.6100 / SP and the decision was unanimous.

The lawsuit was filed by the appellant Cristália Produtos Químicos Farmacêuticos LTDA against Allergan Inc and the Brazilian Patent Office (BPTO).

Cristália claimed that the word “Botox” is indicative of the chemical substance botulinum toxin and therefore it would not be subject to registration. Therefore, the appellant requested the annulment of the trademark registration, owned by Allergan.

The lawsuit was filed in 2006. In a judgment rendered in the first instance, the 19th Federal Civil Court of São Paulo dismissed the lawsuit, but Cristália appealed to the second instance and continued arguing that the registration was in disagreement with the trademark legislation, since the name in question derives from a substance widely used in neurological and aesthetic treatments, and it does not serve to distinguish only the product manufactured by the defendant according to Article 124, VI and XVIII, of Law 9.279 / 96, the Brazilian Industrial Property Law.

However, according to judge Nino Toldo, rapporteur of the case at TRF3, the BPTO’s act of granting the registration of the trademark was “perfectly valid”. The magistrate concluded that the term “Botox” presents the three elements provided for in art. 122 of Law No. 9,279 / 96, necessary to obtain protection and registration as a trademark: Distinctiveness – because it differentiates the product from the company Allergan from those manufactured by other laboratories, such as Botulift (Laboratório Bergamo) and Prosigne (Laboratório Cristália), among others; visually perceptible signs – captured by sight and not by other senses; and no legal prohibition – considering the fences listed in art. 124 of the Industrial Property Law.

Still, the judge understood that the generic character pointed out by Cristália was not characterized in the specific case, because the term “Botox” represents an evocative and suggestive mark of its main component, the botulinum toxin.

“More specifically with regard to its generic character, it should be noted that the word ‘Botox’ is not used to describe the chemical substance itself, which is its main component, and there is no need to speak, therefore, of prohibiting its registration as a trademark. Such a word, by the way, is perfectly capable of individualizing a specific product, within its segment of operation ”, said the judge in his decision.

The vote of the rapporteur judge was followed by all magistrates who are members of the 11th Panel and, by unanimous decision, Cristália’s appeal was denied, the decision of the lower court being upheld.

News from: JOTA

The US orders Chinese consulate to close based on defense of intellectual property

The Chinese consulate in Houston, in the United States, was closed “to protect American intellectual property and private information from Americans” – a State Department spokeswoman said on Wednesday (7/22) after a vigorous protest. Beijing is against that decision.

“Vienna Convention states that state diplomats must ‘respect the laws and rules of the host country’ and ‘have a duty not to interfere in the internal affairs of that state,'” said spokeswoman Morgan Ortagus, during a visit by the American Secretary of State, Mike Pompeo, to Copenhagen.

“We have ordered the closure of the People’s Republic of China consulate in Houston to protect American intellectual property and the private information of citizens,” said the spokeswoman, after Pompeo’s arrival in Copenhagen for an official visit on Wednesday.

This decision is based on the growing tensions between the two countries on several fronts: the controversial national security law in Hong Kong, the espionage charges against China, or the humanitarian situation in the Xinjiang region (northwest China), where the Uighur Muslim minority lives.

“The United States will not tolerate any violation of our sovereignty, nor intimidation of our people by China, nor will we tolerate unfair trade practices, theft of American jobs, and other behavior. President Trump insists on justice and reciprocity in our relations with China, “added the spokeswoman in a statement to the press.

China has five consulates in the United States. The consulate in Houston (Texas) was opened in 1979.

According to Houston newspapers, firefighters went to the Chinese consulate last night because documents were being burned in the building’s courtyard.

On Twitter, local police said smoke was visible, but law enforcement officials “were not allowed to enter” the building.

China reaction

Chinese officials denounced the decision, which they called “political provocation” that will undermine bilateral diplomatic relations.

“It is a political provocation (…) that seriously violates international law,” said a Chinese diplomacy spokesman, Wang Wenbin.

“China condemns this scandalous and unjustified decision,” said Chinese Foreign Ministry spokesman Wang Wenbin, asking Washington to back down, otherwise Beijing will respond in an “appropriate” manner.

Chinese officials accused the United States of “slander” after two citizens of the Asian giant were indicted for cyberattacks on companies involved in the search for a vaccine against the new coronavirus.

The US Department of Justice announced yesterday the accusation against Li Xiaoyu, 34, and Dong Jiazhi, 33, “two Chinese hackers (who) worked with the Chinese Ministry of Security”.

Beijing refuted the charges.

“The Chinese government is a fervent advocate for cybersecurity and has always opposed cyber attacks,” added the spokesman, urging Washington to “end these slanders and defamations” against China.

According to US officials, the two hackers met during their engineering studies and stole thousands of dollars worth of industrial secrets over ten years.

Recently, they reportedly targeted California companies working on a vaccine and treatment for the new coronavirus, according to the federal prosecutor in charge of the case, William Hyslop.

Li and Dong were not arrested and would be in China today.

In this context of escalating tensions, China also warned its students in the United States, on Wednesday, about the risk of suffering “arbitrary interrogation”.

“Recently, the authorities have stepped up arbitrary interrogations, harassment, confiscation of personal property and arrests of Chinese students in the United States,” added China’s Foreign Ministry in a statement.

President Donald Trump’s government has maintained a very critical tone for months with the Chinese authorities, which he accuses of having concealed the magnitude of the spread of COVID-19 since the emergence of the disease in the center of the country in late 2019.

News and photo from: Correio Braziliense


Paraná, one of the States of Brazil, wins its first Green Patent

The city of Cascavel is the first in the State of Paraná to obtain a Green Patent. This nomenclature exists because the patent is related to environmental issues aimed at improving global climate change. The owner of the patent letter is a Doctor in Computational Mechanics, Renato Cesar Pompeu. He developed a combustion engine that reduces the emission of carbon dioxide, which causes the greenhouse effect on the planet. The product will provide greater use of fuel energy, reflecting a more efficient thermal efficiency.

“It took about two and a half years of studies and development for the idea to become an invention. The achievement is immeasurable not only for me but also for our municipality for demonstrating that we have the capacity to create and invent products ”, points out the professor. The “Pompeu engine”, the name given to the invention, is under construction and practical tests on the product should be carried out by the end of the year.

News from: CGN

Brazilian scientists intend to use artificial intelligence to detect COVID-19 through coughing

Brazilian scientists intend to use artificial intelligence to detect COVID-19 through coughing

Scientists at the Butantan Institute and Fiocruz want to train the use of artificial intelligence in the diagnosis of the disease and other lung conditions. The idea of such a program is to detect sound peculiarities that could be indicative of diseases.

The research began this week and its first phase consists of volunteers sending coughing audios. With this, the database obtained will assist in the training of artificial intelligence, which was developed by Intel.

Initially, the goal is to obtain 900 audios, of which 300 of them coming from healthy people, 300 from people diagnosed by Covid-19 by exams, and 300 with other lung diseases. Among healthy people, researchers want to force coughs from people who have had no symptoms of cough, fever, or shortness of breath in the past 30 days.

Participants with Covid-19 must be confirmed by molecular testing (PCR). In this case, the researchers will also collect data such as age, symptom days, respiratory rate, oxygen saturation, among others.

Finally, for the group of people who cough without Covid-19, researchers look for diseases such as bacterial pneumonia, gastroesophageal reflux, asthma, or Chronic Obstructive Pulmonary Disease (COPD).

Only people over 18 can “donate” the cough, which should be done on SoundCov. On the website, the participant must record coughing audio (30 to 60 seconds) and then answer a questionnaire. The data collected by the survey is anonymous.

The public-private partnership was intermediated by the Competitive Brazil Movement (MBC), and also has participation from USP (University of São Paulo) and UFMS (the Federal University of Mato Grosso do Sul).

News from: Diário de Pernambuco

Brazilian scientists discover super therapy to cure AIDS

Brazilian scientists discover super therapy to cure AIDS

A survey conducted by the Federal University of São Paulo (Unifesp) showed that the cure for acquired immunodeficiency syndrome (AIDS) is near. This is the first study, on a global scale, to test overtreatment in individuals chronically infected with the human immunodeficiency virus (HIV).

The coordinator of the research is the infectologist Ricardo Sobhie Diaz. Together with his team, Diaz has been working on two fronts to cure the disease. One uses drugs and substances that kill the virus at the time of replication and eliminate the cells where HIV is asleep (latency); the other develops a vaccine that causes the immune system to react and eliminate infected cells that the drug is unable to reach.

The research was carried out with 30 volunteers with an undetectable viral load, under standard treatment, according to what is currently recommended: the combination of three types of antiretrovirals, better known as “cocktail”. The volunteers were divided into six subgroups, each receiving different combinations of medicines, in addition to the “cocktail” itself.

For members of the subgroup that had the best results so far, two more antiretrovirals were administered: Dolutegravir, the strongest drug currently available on the market; and Maraviroc, a substance that forces the virus, previously hidden, to appear.

News from: Exame


Remdesivir is approved for testing on coronavirus patients in Brazil and Europe

Brazil can already start testing with remdesivir, an antiviral medication, in the treatment of patients with COVID-19, according to a statement made by the Brazilian Health Regulatory Agency (Anvisa) on Wednesday (25).

Anvisa also announced that the study to be carried out in the country will be phase 3, which involves the observation of patients who are being treated with the drug. People who are already hospitalized with severe pneumonia caused by the new coronavirus will receive the drug, divided into two groups.

The first will be treated with remdesivir combined with another medication called tocilizumab, which acts in the body as an immunoregulator and is used against rheumatoid arthritis. The second group will receive remdesivir given with a placebo. The idea is that in Brazil, according to authorization requested by the company PPD do Brasil Suporte a Pesquisa Clínica Ltda, 105 patients pass the test.

Approval in Europe

Remdesivir has also received approval from the European Medicines Agency (EMA), which can now be prescribed for patients diagnosed with COVID-19, requiring mechanical breathing, and who are 12 years of age or older. It is up to the European Commission to finalize the authorization in a bureaucratic manner, which should happen within a week. Once approved, the indication of the drug will be in force in 27 countries and will be valid for one year.

As there is still no proof that the drug is really effective against COVID-19, the North American pharmaceutical manufacturer Gilead needs to inform the European Union of the results of the remdesivir tests, as well as their side effects, by December.

What is Remdesivir for?

Remdesivir is an antiviral developed to combat Ebola, but which has already shown positive results in the treatment of other types of coronavirus, responsible for SARS and MERS diseases. In the United States, the drug has already been approved for serious patients in COVID-19, shortly after authorization by the regulatory agency Food and Drug Administration (FDA).

According to the FDA, the criterion used to approve the drug was a study by the American National Institute of Health (NIH), which conducted tests on 1,063 patients not only in the United States, but in Asia and Europe. The result showed that people treated with remdesivir recovered about four days before those who did not receive the drug. In early June, South Korea and India also began testing the drug.

News from: Canal Tech